[{"id":"397f0e26-37b8-4a9d-b120-14ffdb427e26","acronym":"","url":"https://clinicaltrials.gov/study/NCT03327064","created_at":"2021-01-18T16:25:49.496Z","updated_at":"2024-07-02T16:35:25.146Z","phase":"Phase 1/2","brief_title":"A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer","source_id_and_acronym":"NCT03327064","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 expression","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UAB30"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2023-12-27"},{"id":"8e147cb4-ebf5-4a01-94b5-257d676877de","acronym":"","url":"https://clinicaltrials.gov/study/NCT03323658","created_at":"2021-01-18T16:24:48.075Z","updated_at":"2024-07-02T16:35:57.912Z","phase":"Phase 1","brief_title":"Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer","source_id_and_acronym":"NCT03323658","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Targretin gel (bexarotene topical)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 06/15/2018","start_date":" 06/15/2018","primary_txt":" Primary completion: 08/03/2021","primary_completion_date":" 08/03/2021","study_txt":" Completion: 03/25/2022","study_completion_date":" 03/25/2022","last_update_posted":"2023-01-10"}]